Reformulated: New Takes on Parkinson’s Disease Treatments

[Farooqji]

biospace.com/article/reform...

[ZebraDoodle]

Interesting (if limited) take on the drug pipeline. Seems to be saying CL variants are more likely to be available before a disease modifying treatment but doesn’t mention A-273 or Buntanetap which I would have thought are at a similar way off to the LRRK2 inhibitors and Ambroxol that it does mention. I guess this is seen through the prism of finance reporting and is just one observer’s take. Here’s hoping there’s some good news to prove him wrong.